** Brokerage H.C. Wainwright upgrades drug developer Rapt Therapeutics RAPT.O to 'buy' from 'neutral'
** Co entered into a license agreement with China-based Shanghai Jemincare Pharmaceutical Co for an experimental allergy treatment called RPT904
** RAPT plans to develop RPT904 initially for food allergy
** Brokerage says "investors should note that the food allergy market represents a large and lucrative niche," estimates that about 33 mln people suffer from at least one food allergy in the US
** Brokerage projects peak annual sales of $5.4 bln by 2037 for RPT904, assuming U.S. launch in 2031
** Says RPT904 could achieve peak sales approaching $500M for chronic spontaneous urticaria (CSU) — a skin condition
** Brokerage estimates a 40% probability of approval of RPT904 for food allergy and a 30% probability of approval for CSU
** Up to last close, stock down 93% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.